NCT05429723View on ClinicalTrials.gov

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Cough
Interventions
DRUG

HS-10383

HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.

DRUG

HS-10383 Placebo

Placebo for HS-10383

Trial Locations (1)

250014

RECRUITING

Shandong provincial qianfoshan hospital, Jinan

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY